

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
BREAST CANCER STEERING COMMITTEE (BCSC)								
NCIC CTG -MA.32	Revised & Resubmit; APPROVED	A Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer	Pam Goodwin, MD	3/25/2009; 07/14/2009 (rev)	4/23/2009	7/23/2009	3/26/2010	6/25/2010
ECOG - E2108	Revised & Resubmit; APPROVED	A Randomized Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer	Seema Khan, MD	4/30/2009	6/16/2009	N/A	In Review 11/30/2009	2/8/2011
NSABP - 8708 (NSABP B-48)	Pending with Revisions; Revise & Resubmit; APPROVED	A Randomized Phase III Clinical Trial Evaluating Pathologic Complete Response in Patients with Palpable and Operable, Triple-Negative Breast Cancer Treated with Docetaxel and Cyclophosphamide Followed by Gemcitabine and Carboplatin with or without the PARP1 Inhibitor BSI-201	Steven A, Limentani, MD	10/28/2009	11/19/2009	2/17/2010	In Review 6/30/2010; W/D 06/22/2011	N/A
SWOG-S1007	APPROVED; Revised & Resubmit;	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-9 Positive Nodes, Hormone-responsive and HER2-negative Breast Cancer according to Recurrence Score (RS)	Ana Maria Gonzalez-Angulo, MD	2/24/2010; 5/25/2010 (rev)	3/18/2010	6/16/2010	1/3/2011	01/15/2011
RTOG-1005	APPROVED; Revised & Resubmit;	A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation with Conventional Fractionation plus Sequential Boost for Early-Stage Breast Cancer	Frank A. Vicini, MD, FACR	7/22/2010 10/13/2010 (rev)	8/18/2010	10/20/2010	5/2/2011	5/24/2011
ACOSOG-Z11103	Pending with Revision; APPROVED	ALTERNATE approaches for clinical stage II and III Estrogen Receptor positive breast cancer NeoAdjuvant Treatment (ALTERNATE) Study	Cynthia X. Ma, MD, PhD	3/30/2011; 5/23/2011 (rev 1); 06/08/211 (rev 2)	4/20/2011	6/15/2011		
RTOG-1119	APPROVED (With recommendations)	Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer – A Collaborative Study of RTOG and KROG	In Ah Kim, MD, PhD	8/8/2011	9/15/2011			
BRAIN MALIGNANCY STEERING COMMITTEE (BMSC)								
COG-ACNS1022	Pending Review; APPROVED	A Phase II Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Low-Grade CNS Gliomas	Kathy Warren, MD	12/27/2010	1/13/2011	3/10/2011	In Review 08/19/2011	
C9073 (PBTC-03)	Pending Review; APPROVED	A Feasibility and Phase II Study of ABT888, an oral poly(ADP-ribose) polymerase inhibitor, and concurrent radiation therapy, followed by ABT888 and temozolomide, in children with newly diagnosed high-grade or diffuse pontine gliomas (DIPG)	Jack Meng-Fen Su, MD	05/04/2011 (rev1)	3/10/2011	5/12/2011	In Review 08/31/2011	

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
COG-ACNS1123	Pending Review; APPROVED (with Recommendations)	Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors	Ute Bartels, MD	5/25/2011; 8/31/2011	7/14/2011	9/8/2011		
CLINICAL IMAGING STEERING COMMITTEE (CISC)								
CALGB_71101	APPROVED	Change in Mammographic Density with Metformin Use: A Companion Study to NCIC study MA.32	Jennifer Eng-Wong, MD, MPH	7/25/2011	8/9/2011			
ACRIN_6698 (#9175)	APPROVED	MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis)	Nola Hylton, PhD.	8/15/2011	9/13/2011			
GYNECOLOGIC CANCER STEERING COMMITTEE (GCSC)								
GOG-0213	Pending with Revisions; APPROVED	A Phase 3 Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab or in Combination with Bevacizumab Followed by Bevacizumab and Erlotinib and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian and Peritoneal Primary Cancer	Robert L. Coleman, MD	10/26/04; revision 1 - 6/14/05; revision 2 - 7/5/05; 8/16/06	9/28/2006	1/9/2007	10/19/2007	12/6/2007
GOG-0238	APPROVED	A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Higinia R. Cardenes, MD, PhD	NOT A CONCEPT; Study came to PIO as Protocol; 12/12/2006	2/23/2007	N/A	5/11/2007	2/25/2008
UC-0704 (GOG-0258)	APPROVED	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Daniela Matei, MD	5/29/2007	7/9/2007	N/A	6/29/2009	6/29/2009
LOI 8093 (GOG-0248)	APPROVED	Randomized Phase II Trial of Temsirolimus or the Combination of Hormonal Therapy Plus Temsirolimus in Women with Advanced or Recurrent Endometrial Carcinoma	Gini Fleming, MD	Not a CONCEPT; LOI; 4/6/2007	5/8/2007	N/A	7/28/2008	9/29/2008
GOG-0204R-CVM-0704 (GOG-0240)	APPROVED	A Randomized Phase III Trial of Cisplatin plus Paclitaxel with and without Bevacizumab versus the Non-Platinum Doublet, Topotecan plus Paclitaxel, with and without Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Krishnansu S. Tewari, MD	NOT A CONCEPT; Protocol; 05/31/07	6/25/2007	N/A	11/21/2008	4/6/2009
UC-0701 (GOG-0261)	APPROVED	Randomized Phase III Trial of Carboplatin plus Paclitaxel versus Ifosfamide plus Taxol in Patients with Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus	Matthew A. Powell, MD	7/31/2007	8/7/2007	N/A	7/23/2009	8/17/2009

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
UC-0604 (2007) (GOG-0249)	APPROVED	Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Cancer	Scott McMeekin, MD	08/21/06; 10/09/07 (rev)	11/6/2007	N/A	12/1/2008	3/23/2009
GOG - OVM0606	APPROVED; (Withdrawn)	A Randomized Phase III Trial of Neoadjuvant Carboplatin/ Paclitaxel vs. Carboplatin/Weekly Abraxane in Performance Status Challenged and Geriatric Patients	Thomas J. Herzog, MD	N/A - sent directly to Ovarian TF	11/6/2007	N/A	N/A	W/D
GOG - DTM 0708	APPROVED; (Withdrawn)	A Randomized Phase II Evaluation of Volociximab (M200) plus Weekly Paclitaxel vs. Weekly Paclitaxel Alone in the Third-line Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GOG-0186 series)	Linda A. Duska, MD	N/A - sent directly to Uterine TF	9/11/2007	N/A	N/A	W/D
OVM0705 (GOG-0252)	APPROVED	Phase III Clinical Trial of Bevacizumab with IV versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Joan L. Walker, MD	12/14/2007	1/8/2008	N/A	7/20/2009	7/27/2009
RTOG-0724	Pending with Revisions; APPROVED	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy	Anuja Jhingran, MD	9/25/2007; 3/24/2009	6/9/2008	9/9/2008	8/10/2009	9/16/2009
OVM0703 (GOG-0255)	APPROVED	A Randomized Phase III Trial in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer with a Polyvalent Vaccine-KLH Conjugate + QS-21 versus QS-21	Paul Sabbatini, MD	4/22/2008	5/13/2008	N/A	2/19/2009	7/26/2010
GOG-0241	Revised and Submitted; APPROVED;	A Randomized Phase III Evaluation of Capecitabine and Oxaliplatin (Xelox) versus Carboplatin and Paclitaxel in Mucinous Adenocarcinoma of the Ovary	David M. Gershenson, MD	01/04/08; 04/16/08 (rev); 12/30/08 (rev); 02/04/10 (rev)	5/13/2008	1/20/2009	9/8/2010	10/12/2010
DTM0720 (GOG-0250)	APPROVED	Randomized Phase IIB Evaluation of Gemcitabine-Docetaxel with or without Bevacizumab for Advanced or Recurrent Uterine Leiomyosarcoma	Martee L. Hensley, MD	2/25/2008; 03/17/2006 (rev)	4/7/2008	N/A	10/19/2009	11/9/2009
CVM0801 (GOG 0263)	APPROVED	Randomized Clinical Trial for Adjuvant Chemo-radiation in Post-operative Cervical Cancer Patients with Intermediate Risk Factors	Sang Young Ryu, MD	03/26/08; 04/24/08 (rev); 01/30/09 (rev)	2/17/2009	N/A	4/1/2010	4/12/2010
RTM0602 (GOG 0264)	Pending with Revisions/ APPROVED	A Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage Sex Cord-Stromal Tumors of the Ovary	Jubilee Brown, MD	4/28/2009	5/19/2009		12/29/2009	2/8/2010
DTM0801 (GOG - 0186G)	APPROVED	A Randomized Phase II Evaluation of Oral Everolimus (RAD001) plus Bevacizumab vs. Oral Placebo plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	William P. Tew, MD	8/7/2008; 10/28/08 (rev)	11/18/2008	N/A	4/6/2009	12/27/2010

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
SWOG-S0904	APPROVED	Randomized Phase II Study of Docetaxel Followed by ZD6474 (Vandetanib) vs. Docetaxel plus ZD6474 in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	Robert L. Coleman, MD	8/19/2008; 10/28/2008 (rev)	11/18/2008	N/A	3/17/2009	3/15/2010
OVM0813 (GOG 0262)	Pending with Revisions; APPROVED	A Randomized Phase III Trial of Every-Three-Weeks versus Dose Dense Weekly Paclitaxel and Carboplatin plus Concurrent Bevacizumab in the Treatment of Primary Suboptimal Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma	John K. Chan, MD	11/10/2008; 3/10/2009 (rev)	12/1/2008	1/20/09, 3/17/09, 4/7/09	7/2/2010	9/27/2010
DTM0905 (GOG - 01861)	APPROVED	A Randomized Phase II Evaluation of Single Agent Bevacizumab (NSC #704865) and Combination Bevacizumab with Fosbretabulin in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	Bradley J. Monk, MD	9/29/2009	10/20/2009	N/A	2/22/2011	3/12/2011
NCIC CTG - OV.21	APPROVED	A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy	Helen Mackay, MD	11/9/2009	11/17/2009	N/A	11/1/2010	9/11/2009
SWOG - S0903	APPROVED; (Withdrawn)	Randomized Phase II Study Evaluating Carboplatin/Paclitaxel Compared with Carboplatin/Paclitaxel and Everolimus in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in First Relapse	Lainie P. Martin, MD	3/29/2010	4/20/2010	N/A	In Review 07/29/2010	W/D
CVM1004 (ANZGOG-0902; GOG-0274)	Pending with Recommendations; APPROVED	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: GOG COLLABORATION WITH THE OUTBACK TRIAL (ANZGOG 0902)	Kathleen Moore, MD	3/30/2010 7/2/2010 (rev)	4/20/2010	7/20/2010	7/22/2011	
DTM1003 (GOG-0186J)	APPROVED	A Randomized Phase IIB Evaluation of Pazopanib versus Weekly Paclitaxel plus Pazopanib versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	Debra L. Richardson, MD	6/15/2010	7/20/2010	N/A	In Review 03/29/2011	
GOG - DTM 0929	APPROVED; (Withdrawn)	A Phase II Study Of The Potent, Highly Selective Poly(Adp-Ribose) Polymerase (Parp) -1 And -2 Inhibitor Mk-4827 In The Treatment Of Persistent Or Recurrent High-Grade Serous Ovarian Cancer	Robert L. Coleman, MD	10/21/2010	11/16/2010	N/A	N/A	W/D
GOG - 0270	Pending with Revision; APPROVED	Groningen International Study on Sentinal Nodes in Vulvar Cancer (Groinss-V) II: An Observational Study	Brian M. Slomovitz, MD	11/24/2010 05/10/11 (rev)	1/18/2011	5/31/2011	In Review 09/28/2011	

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
GOG -UC1009	Pending with Revision; APPROVED	A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. Letrozole for Early Stage High Grade Uterine Leiomyosarcoma	Martee L. Hensley, MD	3/23/2011; 06/22/2011 -(rev)	4/19/2011	7/12/2011		

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
GOG - UC1005	APPROVED	A Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Treatment of Low-risk Gestational Trophoblastic Neoplasia	Julian C. Schink, MD	4/28/2011	5/17/2011	N/A		
GASTROINTESTINAL CANCER STEERING COMMITTEE (GISC)								
RTOG-0436	Pending with Revisions/ APPROVED	A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Locally Advanced Esophageal Cancer	Mohan Suntharalingam, MD	09/20/06 (rev); 12/12/06 (rev2)	10/16/2006	12/18/2006	10/27/2007; 12/11/2007	6/30/2008
ACOSOG Z6051	Pending with Revisions/ APPROVED	A Phase III Trial Comparing Laparoscopic-Assisted Rectal Resection (LARR) to Open Resection for Rectal Cancer	James Fleshman, MD	4/2/2007	5/21/2007	7/16/2007	7/22/2008	8/15/2008
USMCI - 8214	APPROVED	A Phase III Trial Comparing Best Available Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C + Best Available Systemic Therapy in Patients with Limited Peritoneal Dissemination of Colon Adenocarcinoma	Alex Stojadinovic, MD, Jesus Esquivel, MD	12/5/2007	12/17/2007	N/A	7/7/2010	8/20/2010
CALGB-80701	Pending with Revisions/ APPROVED	A Phase II Randomized Study of Temozolamide or Temozolamide + Bevacizumab in Patients with Advanced Pancreatic Neuroendocrine Tumors	Matt Kulke, MD	12/3/2007; 05/12/08 (rev)	12/17/2007	5/19/2008	In Review 2/19/2009	10/15/2010
CALGB-80802	Pending with Revisions/ APPROVED	Phase II/III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)	Abou-Alfa Ghassan, MD	4/10/2008; 08/07/08 (rev)	5/19/2008	8/18/2008	11/2/2009	2/15/2010
ECOG - E1208	Pending with Revisions/ APPROVED	A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.	John Kauh, MD	5/27/2008; 6/9/2008 (rev); 9/8/2007 (rev)	6/16/2008	9/15/2008	10/5/2009	10/28/2009
CALGB-80702	Pending with Revisions/ APPROVED	A 2 x 2 Phase III Trial of Celecoxib and Vitamin D in Addition to Standard Chemotherapy for Stage III Colon Cancer	Jeffrey A. Meyerhardt, MD	7/7/2008, 10/13/2008, 2/21/2009	7/21/2008	11/17/2008 and 2/27/2009	6/15/2010	6/22/2010
RTOG-0848	Pending with Revisions/ APPROVED	Gemcitabine, With and Without Erlotinib, Followed By a Second Randomization With and Without Chemoradiation, as Adjuvant Treatment For Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study	Ross Abrams, MD	8/8/2008; 11/10/2008	8/18/2008	11/17/2008	10/23/2009	11/17/2009
8358 (NSABP-C-11)	Pending with Revisions/ APPROVED	Phase III Trial Evaluating the Role of Perioperative Chemotherapy and Bevacizumab in Patients with Potentially Resectable Hepatic Colorectal Metastases	Michael Choti, MD	12/22/2008; 04/13/09 (rev)	1/26/2009	4/20/2009	7/29/2010	8/23/2010

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
ECOG - E7208	Pending with Revisions/ APPROVED	A Randomized Phase II Study of Irinotecan with Cetuximab Plus/Minus IMC-1121B in Metastatic Colorectal Cancer Patients Progressing on Bevacizumab-Containing Chemotherapy	Howard S. Hochster, MD	2/3/2009	2/27/2009	5/18/2009	2/22/2010	10/8/2010
RTOG-1010	Pending Review; APPROVED	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2 Overexpressing Esophageal Adenocarcinoma	Howard Safran, MD	09/25/2009; 10/23/2009 (rev)	11/16/2009	1/11/2010	8/11/2010	12/30/2010
NCCTG - N0949	Revised and Resubmitted; APPROVED	Randomized Phase III Trial of mFOLFOX7 Plus Bevacizumab Versus 5-Fluorouracil or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients (≥75Years Old) with Metastatic Colorectal Cancer	Alex Grothey, MD	3/29/2010	4/19/2010	6/21/2010	12/23/2010	01/21/2011
CALGB-80803	Pending with Revisions APPROVED	Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer	Kathryn A. Goodman, MD	4/20/2010	6/21/2010	8/16/2010	4/4/2011	7/15/2011
NCCTG N1048/ CALGB 81001/ ACOSOG Z6092	Pending with Revisions; APPROVED	A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	Deborah Schrag MD (CALGB) , Alessandro Fichera (ACOSOG) Robert McWilliams Mayo Clinic (NCCTG)	1/20/2011	2/28/2011	4/4/2011		
CALGB-81003	APPROVED	Phase IB/Randomized Phase II Study of Folfirinox plus AMG-479 or placebo in Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma	Brian M. Wolpin, MD, MPH	2/17/2011	3/28/2011	N/A	In Review 08/01/2011	
SWOG - S1115	Pending with Revisions; APPROVED	Randomized Phase II Clinical Trial of AZD-6244 and MK-2206 vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy	Vincent Chung, MD	6/1/2011	7/18/2011	8/15/2011		
SWOG -S1201	APPROVED	A Randomized Phase II Pilot Study Prospectively Assigning Treatment for Patients Based on ERCC1 for Advanced/Metastatic Gastric Cancer or Gastroesophageal (GE) Junction Cancer	Syma Igbal, MD	6/27/2011	8/15/2011			

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
GENITOURINARY CANCER STEERING COMMITTEE (GUSC)								
RTOG 0815	Pending with Revisions/ APPROVED	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer	Alvaro A. Martinez, MD	7/11/08 11/7/08	8/20/2008	11/19/2008	6/18/2009	9/14/2009
CALGB-90802	APPROVED	Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors.	George K. Philips, MD	7/21/2008	9/17/2008	N/A	8/19/2010	9/15/2010
CALGB-90901	Pending with Revision/ APPROVED; (Withdrawn)	A Randomized Phase III Study of ixabepilone, mitoxantrone and prednisone versus mitoxantrone and prednisone alone in patients with castration resistant prostate cancer previously treated with docetaxel chemotherapy.	Charles Ryan, MD	4/1/2009	6/17/2009	8/19/2009	No protocol rec'd	W/D
SWOG - S0931	APPROVED	EVEREST: EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study	Christopher Ryan, MD	4/3/2009	5/20/2009	N/A	3/15/2010	4/1/2011
SWOG - S1011	Approved	Prospective Evaluation Of The Benefit Of A Standard Versus An Extended Pelvic Lymphadenectomy Performed At Time Of Radical Cystectomy For Bladder Cancer With Adjuvant Chemotherapy Administration For Node Positive Disease	Seth Paul Lerner, MD	3/31/2010	4/21/2010	N/A	09/30/2010; 01/07/2011 (rev)	8/1/2011
RTOG-0924	Pending with Revisions; Approved	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	Mack Roach III, MD	6/2/2010; 10/14/2010 (rev)	7/21/2010	10/20/2010	5/24/2010	7/7/2011
ECOG - E2810	Pending with Revisions; APPROVED (On HOLD)	Randomized, double-blind phase III study of pazopanib vs. placebo in subjects with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy	Leonard J. Appleman, MD, PhD	3/30/2011; 6/8/2011 (rev)	4/20/2011	7/20/2011		
RTOG-1115	APPROVED	Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700	M. Dror Michaelson, MD	2/14/2011	5/4/2011	N/A	In Review 09/30/2011	
HEAD & NECK CANCER STEERING COMMITTEE (HNCS)								
RTOG-0920	APPROVED	Phase III Randomized Study of Adjuvant Intensity-Modulated Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Resected Squamous Cell Carcinoma of the Head and Neck	Mitchell Machtay, MD	1/9/2008; 5/8/2008	2/1/2008	5/5/08 and 8/4/08	7/22/2009	11/5/2009
ACRIN - 6685 (#8270)	Pending with Revisions/ APPROVED	FDG PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck	Val Lowe, MD	4/30/2008	11/3/2008	2/23/2009	9/2/2009	4/1/2010

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
RTOG-1008	APPROVED	A Randomized Phase II Study of Adjuvant Concurrent Chemotherapy and Radiation in Resected High-Risk Malignant Salivary Gland Tumors	Cristina P. Rodriguez, MD; David Adelstein, MD	2/1/2010	5/3/2010	N/A	9/17/2010	11/3/2010
RTOG-1016	Pending with Revisions/ APPROVED	Phase II-III Trial of Moderate De-Escalation of Chemotherapy and Radiation in Favorable Risk, Locally Advanced, HPV-Associated Oropharynx Cancer	Andy Trotti, MD	3/22/2010	4/12/2010	7/12/10	2/15/2011	6/9/2011
LEUKEMIA CANCER STEERING COMMITTEE (LKSC)								
CALGB-11002	APPROVED	A Randomized Phase II Trial of Decitabine-based Induction Strategies for Patients ≥ 60 Years Old with Acute Myeloid Leukemia	Gail J. Roboz, MD	6/24/2010; 9/20/2010 (Rev)	7/27/2010	9/28/2010	In Review 6/3/2011	
SWOG - S1117	APPROVED	A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide vs. Azacitidine in Combination with Vorinostat vs. Azacitidine Alone for Higher-Risk Myelodysplastic Syndromes (MDS)	Mikkael A. Sekeres, MD	6/8/2011	6/28/2011			
LYMPHOMA CANCER STEERING COMMITTEE (LYSC)								
ECOG - E1410	APPROVED; (Withdrawn)	Intergroup Randomized Phase 2 Three-Arm Study In Patients <input type="checkbox"/> 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine (R – B), Arm B = Rituximab + Bendamustine + Bortezomib (R - B – V), or Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (R - B → L – R)	Mitchell Smith, MD, PhD	9/1/2010	10/8/2010	N/A	N/A	W/D
SWOG - S1001	Revise & Resubmit; APPROVED	A Phase II Trial of PET-directed Therapy for Early Stage Diffuse Large B-cell Lymphoma	Daniel O. Persky, MD	10/6/2010; 01/24/2011	12/10/2010	2/11/2011	5/16/2011	
ECOG - E2410	APPROVED	Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL)	Ranjana Advani, MD	1/21/2011	2/11/2011	N/A	6/21/2011	
SWOG - S1106	APPROVED	A Randomized Phase II Trial of R-HCVAD-MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Previously Untreated Patients ≤ 65 Years of Age With Mantle Cell Lymphoma	Steven H. Bernstein, MD	1/28/2011	3/11/2011	N/A	7/29/2011	

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
<p>ECOG - E1411 [formerly ECOG E1410]</p>	<p>APPROVED</p>	<p>Intergroup Randomized Phase 2 Four Arm Study In Patients <input type="checkbox"/> 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)</p>	<p>Mitchell Smith, MD, PhD</p>	<p>2/18/2011</p>	<p>3/11/2011</p>	<p>N/A</p>	<p>7/29/2011</p>	
<p>CALGB - 51101</p>	<p>APPROVED</p>	<p>Randomized trial of myeloablative versus non-myeloablative consolidation chemotherapy for newly diagnosed primary CNS B-cell lymphoma</p>	<p>Tracey Batchelor, MD</p>	<p>5/23/2011</p>	<p>7/8/2011</p>	<p>N/A</p>		

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
MYELOMA CANCER STEERING COMMITTEE (MYSC)								
ECOG - E1A10	APPROVED	A Randomized Selection Phase II Study of Rituximab, Bortezomib, and Dexamethasone and Rituximab, RAD001, and Dexamethasone in Previously Untreated, Symptomatic Waldenström's Macroglobulinemia	Leonard T. Heffner, Jr.	5/13/2010; 5/28/2010	7/6/2010	9/7/2010	5/27/2011	7/20/2011
PEDIATRIC LEUKEMIA AND LYMPHOMA STEERING COMMITTEE (PLLSC)								
COG - ANHL1131	Pending Revision; APPROVED (with Recommendations)	Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients.	Thomas G. Gross, MD, Ph.D	4/29/2011; 7/22/2011	6/3/2011	8/5/2011		
PEDIATRIC AND ADOLESCENT SOLID TUMOR STEERING COMMITTEE (PASTSC)								
COG - ANBL1122	APPROVED (on hold)	Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus or Bevacizumab (Avastin) in Children with Relapsed Neuroblastoma	Rajen Mody, MD, MS	6/29/2011	7/25/2011			
COG - ADVL1122	APPROVED (with recommendations)	A Phase II Trial of Pazopanib (NSC# 737754, IND# 75648) in Children with Refractory Solid Tumors"	Alice Lee, M.D	8/19/2011	9/26/2011			
SYMPTOM MANAGEMENT & QUALITY OF LIFE STEERING COMMITTEE (SxQL)								
NCCTG - N08C3	APPROVED	Phase III Double-Blind, Placebo Controlled Study of Gabapentin for the Treatment of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy	Deborah Barton, RN, PhD	2/12/2008	3/11/2008	N/A	1/28/2009	4/17/2009
Wake Forest Research Base (WFU-08-03-06)	Revise/Resubmit/ APPROVED	Phase II Randomized Placebo Controlled Study of Armodafinil on Fatigue in Brain Tumor Patients Receiving Brain Radiation Therapy	Edward G. Shaw, MD	3/12/2008	4/8/2008	7/8/2008	12/3/2009	8/5/2010
NCCTG - N08C7	APPROVED	Phase III, Randomized, Placebo-controlled, Double-Blind Trial of Flaxseed for the Treatment of Hot Flashes	Deborah Barton, RN, PhD	5/14/2008	6/10/2008	N/A	5/27/2009	10/9/2009
Wake Forest Research Base (WFU-08-08-08)	Revise/Resubmit/ APPROVED	Yoga during Breast Cancer Treatment: Establishing Community-Based Partnerships	Suzanne Danhauer, PhD	8/18/2008	9/9/2008	1/13/2009	6/22/2009	10/21/2009
Wake Forest Research Base (WFU-08-08-09)	Revise/Resubmit/ APPROVED	A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for Its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy	James Urbanic, MD	8/14/2008	9/9/2008	2/10/2009	3/26/2010	10/18/2010
Moffitt Research Base (HLMCC-0806)	Revise/Resubmit/ APPROVED	Phase II Placebo-controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (neo)Adjuvant Chemotherapy with Trastuzumab (Herceptin)	Maya Guglin, MD	8/25/2008	10/14/2008	1/13/2009	8/31/2009	3/1/2010

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
NCCTG-N08CB	Revise/Resubmit/ APPROVED	A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity	Charles Loprinzi, MD	9/12/2008	10/14/2008	1/13/2009	3/29/2010	6/22/2010
GOG 0257	Revise/Resubmit/ APPROVED	A Randomized, Double-Blind, Placebo Controlled Trial Using Acetyl L-Carnitine (ALCAR) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients with Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	David Kushner, MD	9/26/2008	11/18/2008	4/14/2009	In Review	
URCC-09005	Revised & Resubmit; APPROVED	Curcumin for the Prevention of Radiation-Induced Dermatitis in Breast Cancer Patients	Juli Ryan, MD, MPH	2/19/2009	4/14/2009	12/8/2009	10/25/2010	10/25/2010
SWOG-S0927	Revise & Resubmit; APPROVED	Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer	Dawn Hershman, MD, MS	4/3/2009	5/12/2009	11/10/2009	10/4/2010	
NCCTG - N09C6	Revise & Resubmit; APPROVED	Phase III Double-Blind Cross-over Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy and/or Chemotherapy	James L. Leenstra MD; Robert C. Miller, MD	7/24/2009	9/8/2009	12/8/2009	6/9/2010	12/17/2010
RTOG-1012	APPROVED	Phase II Randomized Dose Seeking Trial of the Prophylactic Use of Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis During the Treatment of Lung Cancer	Lawrence B. Berk, MD	10/20/2009	12/8/2009	N/A	11/23/2010	
RTOG 0938	Revise & Resubmit; APPROVED	A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer	Jean-Paul Bahary, MD	3/8/2010; 8/18/2010 (rev)	4/20/2010	9/14/2010	11/23/2010	
NCCTG - N10C1	Approved	Vaginal DHEA for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study	Debra Barton MD	5/7/2010	5/11/2010	N/A	5/18/2011	7/29/2011
NCCTG - N10C2	Revise & Resubmit ; APPROVED	Phase III Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes	Haeseong Park, MD, MPH	8/12/2010; 3/3/2011 (rev 1)	9/14/2010	3/8/2011	9/1/2011	9/30/2011
Wake Forest Research Base (WFU 10-05-16)	APPROVED	A Feasibility Study of Donepezil in Breast Cancer Survivors with Chemotherapy-Related Self-Reported Cognitive Dysfunction	Julia Lawrence, DO	5/12/2010	8/10/2010	N/A	In Review	
NCCTG - N10CB	Revise & Resubmit; APPROVED	A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® versus Placebo in the Prevention of Acute Radiation Enteritis in Patients Receiving Abdominal and/or Pelvic Radiation Therapy	Robert C. Miller MD & Christopher L. Hallemeier, MD	12/20/2011; 3/16/2011 (rev)	1/11/2011	4/12/2011	In Review	
NCCTG - N10C7	Revise & Resubmit; APPROVED	A Randomized Double-blind Placebo Controlled, Phase II/III, Study of Aromatase Inhibitors and Transdermal Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgia	Stephen Birrell, MD, PhD	1/14/2011; 06/13/2011	3/8/2011	7/12/2011		

Study Number	Status	Study Title	Principal Investigator	Date Received in PIO (for SC evaluation)	Date Original Reviewed in SC	Date of Re-Review in SC (if applicable)	Date Protocol Approved by NCI	Date Protocol Open to Accrual
THORACIC MALIGNANCY STEERING COMMITTEE (TMSC)								
RTOG 0937	Pending with Revisions/ APPROVED	Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)	Elizabeth Gore, MD	5/7/2009 7/30/2009	5/21/2009	8/20/2009	1/12/2010	3/18/2010
RTOG 1021 (formerly ACOSOG Z4099)	APPROVED	A Randomized Phase III Study of Sublobar Resection versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)	Hiran C. Fernando, MD (ACOSOG); and Robert Timmerman, MD (RTOG)	2/22/2010	3/18/2010	N/A	4/11/2011	5/2/2011
RTOG-1106	Pending Review ; APPROVED	Randomized Phase II Trial of Individualized Adaptive Radiation Using During-Treatment FDG-PET/CT and Modern Radiation Technology to Dose Escalate in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	Feng Ming (Spring) Kong, MD, PhD	1/4/2011; 4/14/2011 (rev1);	2/17/2011	5/5/2011	In Review 07/08/2011	
ACOSOG Z41102	APPROVED	Personalized Adjuvant Therapy In Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)	Ramaswamy Govindan, MD	3/29/2011	5/5/2011			